To validate these findings in vivo, we evaluated the expression levels of CD80, VISTA, LAG-3, SIRP-α and TIM-3 on freshly isolated Ly6C+ monocytes, derived from healthy, Ctrl or anti-PD-L1 mAb treated tumor-bearing mice. This evidence concerns the gene CD80 and neoplasm.